TUCSON, AZ / ACCESS Newswire / February 2, 2026 / Umbrella Labs today announced an expanded research procurement program for ...

Sermorelin, a synthetic analog of growth hormone–releasing hormone (GHRH 1–29), has long attracted scientific interest due to ...

Stefan Bornstein, MD, PhD, professor, made it clear during a press conference at the 67th Congress of the German Society of Endocrinology (DGE) that there is more than one interaction between them.

This specific 1-29 sequence is often referred to as the "functional fragment" because it contains the essential binding domain required to activate GHRH receptors in the pituitary gland.

In some cases, HR-positive/HER2-negative breast cancers may over time become resistant to endocrine therapy. This can occur through mutations in the estrogen receptor ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

New review reveals how non-genomic estrogen signaling undermines treatment response and fuels tumor progression Hormone receptor–positive breast ...

Hormones control essential processes like growth, metabolism, mood, and reproduction, but when their balance is disrupted, it ...